Keyphrases
Favipiravir
100%
SARS-CoV-2 Infection
100%
Review Protocol
100%
MRNA-1273
100%
Injection Site Reaction
100%
Retrospective Longitudinal Study
100%
Vaccination
100%
Japan
100%
Screening Decisions
100%
Umbrella Review
100%
Decision Aid
100%
Overview of Reviews
100%
Screening Effect
75%
Time to Defervescence
60%
Old Japanese
50%
Attendance Rate
50%
Intention to Screen
50%
Self-selection Bias
50%
Second Dose
50%
First Dose
50%
Late Treatment
40%
Presentation Format
33%
Bias Correction
25%
East Asian Studies
25%
Per-protocol Effect
25%
Data Assessment
25%
Broad-spectrum Inhibitor
20%
Viral RNA-dependent RNA Polymerase
20%
Option Selection
16%
Non-randomized Studies of Interventions
16%
Actual Choice
16%
Assessment Measures
16%
Psychosocial Outcomes
16%
Decision Preference
16%
Tool Management
16%
Quality of Delivery
16%
Course of COVID-19
11%
Nasopharyngeal Sample
11%
Discussion Frequency
7%
Alternative Format
7%
Screening Uptake
7%
Breast Cancer Screening
7%
Citation Count
7%
Individual Reviews
7%
Dual Screening
7%
Overview of Systematic Reviews
7%
Preference-based
7%
Medicine and Dentistry
Injection Site Reaction
100%
Reverse Transcription Loop Mediated Isothermal Amplification
100%
Umbrella Review
100%
Cross Sectional Study
100%
Favipiravir
100%
Recurrent Disease
50%
Mass Radiography
25%
RNA Directed RNA Polymerase
20%
Breast Cancer Screening
12%
Nasopharyngeal Swab
11%
Pharmacology, Toxicology and Pharmaceutical Science
Favipiravir
100%
Malignant Neoplasm
100%
Randomized Controlled Trial
30%
Prostate Cancer
20%
RNA Directed RNA Polymerase
20%
Breast Cancer
20%
Colorectal Carcinoma
20%
Lung Cancer
10%